Effect of route of administration and age on the pharmacokinetics of amikacin administered by the intravenous and intraosseous routes to 3 and 5‐day‐old foals

M. RENÉE GOLENZ, William D Wilson, Gary Carlson, THERESE J. CRAYCHEE, JUDITH E. MIHALYI, LINDA KNOX

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The suitability of the intraosseous (i.o.) route for drug administration to equine neonates was evaluated in a study comparing the pharmacokinetics of amikacin administered by the i.o. and intravenous (i.v.) routes. Using a cross‐over study design amikacin sulphate (7 mg/kg bwt) was administered i.o. or i.v. to 6 healthy foals at 3 and 5 days of age. Amikacin was instantaneously and completely absorbed after i.o. administration, achieving a mean ± sd peak concentration (34.17 ± 3.54 μg/ml) in the first sample collected 3 min after administration which was not significantly different from the mean ± sd peak concentration (32.92 ± 2.63 μg/ml) achieved after i.v. administration. The plasma amikacin concentration‐time profiles for the i.o. and i.v. routes were not different and both were appropriately described by a 2‐compartment open pharmacokinetic model. No significant differences attributable to route of administration were found in values for the major pharmacokinetic variables. The degree of inter‐individual variation in values for indices of clearance was considerably greater than the degree of variation attributable to age. Despite this, values for body clearance (C***lB) were significantly higher (P<0.05) and values for area under the plasma amikacin concentration‐time curve (AUC) and concentration of amikacin in plasma at 8 h [Cp(8h)] were significantly lower in 5‐ than in 3‐day‐old foals, indicating that amikacin was more rapidly cleared by the older foals. Technical difficulties were not encountered during i.o. needle placement in the medial aspect of the proximal tibia. Mild diffuse soft tissue swelling which developed at the i.o. site resolved completely within 1–2 months. Radiographs demonstrated a bony healing process with minor periosteal and endosteal proliferation. The i.o. route appears to be safe, practical and effective for rapid delivery of amikacin to neonatal foals.

Original languageEnglish (US)
Pages (from-to)367-373
Number of pages7
JournalEquine Veterinary Journal
Volume26
Issue number5
DOIs
StatePublished - 1994

Fingerprint

amikacin
Amikacin
foals
pharmacokinetics
Pharmacokinetics
Cross-Over Studies
Drug Administration Routes
drug delivery systems
tibia
Tibia
intravenous injection
Intravenous Administration
Horses
Area Under Curve
Needles
sulfates
neonates
experimental design
horses

Keywords

  • amikacin
  • foal
  • horse
  • intraosseous
  • pharmacokinetics

ASJC Scopus subject areas

  • Equine

Cite this

Effect of route of administration and age on the pharmacokinetics of amikacin administered by the intravenous and intraosseous routes to 3 and 5‐day‐old foals. / GOLENZ, M. RENÉE; Wilson, William D; Carlson, Gary; CRAYCHEE, THERESE J.; MIHALYI, JUDITH E.; KNOX, LINDA.

In: Equine Veterinary Journal, Vol. 26, No. 5, 1994, p. 367-373.

Research output: Contribution to journalArticle

@article{dc63a826ecf54c8da872938b3715feda,
title = "Effect of route of administration and age on the pharmacokinetics of amikacin administered by the intravenous and intraosseous routes to 3 and 5‐day‐old foals",
abstract = "The suitability of the intraosseous (i.o.) route for drug administration to equine neonates was evaluated in a study comparing the pharmacokinetics of amikacin administered by the i.o. and intravenous (i.v.) routes. Using a cross‐over study design amikacin sulphate (7 mg/kg bwt) was administered i.o. or i.v. to 6 healthy foals at 3 and 5 days of age. Amikacin was instantaneously and completely absorbed after i.o. administration, achieving a mean ± sd peak concentration (34.17 ± 3.54 μg/ml) in the first sample collected 3 min after administration which was not significantly different from the mean ± sd peak concentration (32.92 ± 2.63 μg/ml) achieved after i.v. administration. The plasma amikacin concentration‐time profiles for the i.o. and i.v. routes were not different and both were appropriately described by a 2‐compartment open pharmacokinetic model. No significant differences attributable to route of administration were found in values for the major pharmacokinetic variables. The degree of inter‐individual variation in values for indices of clearance was considerably greater than the degree of variation attributable to age. Despite this, values for body clearance (C***lB) were significantly higher (P<0.05) and values for area under the plasma amikacin concentration‐time curve (AUC) and concentration of amikacin in plasma at 8 h [Cp(8h)] were significantly lower in 5‐ than in 3‐day‐old foals, indicating that amikacin was more rapidly cleared by the older foals. Technical difficulties were not encountered during i.o. needle placement in the medial aspect of the proximal tibia. Mild diffuse soft tissue swelling which developed at the i.o. site resolved completely within 1–2 months. Radiographs demonstrated a bony healing process with minor periosteal and endosteal proliferation. The i.o. route appears to be safe, practical and effective for rapid delivery of amikacin to neonatal foals.",
keywords = "amikacin, foal, horse, intraosseous, pharmacokinetics",
author = "GOLENZ, {M. REN{\'E}E} and Wilson, {William D} and Gary Carlson and CRAYCHEE, {THERESE J.} and MIHALYI, {JUDITH E.} and LINDA KNOX",
year = "1994",
doi = "10.1111/j.2042-3306.1994.tb04405.x",
language = "English (US)",
volume = "26",
pages = "367--373",
journal = "Equine veterinary journal. Supplement",
issn = "2042-3306",
publisher = "British Equine Veterinary Association",
number = "5",

}

TY - JOUR

T1 - Effect of route of administration and age on the pharmacokinetics of amikacin administered by the intravenous and intraosseous routes to 3 and 5‐day‐old foals

AU - GOLENZ, M. RENÉE

AU - Wilson, William D

AU - Carlson, Gary

AU - CRAYCHEE, THERESE J.

AU - MIHALYI, JUDITH E.

AU - KNOX, LINDA

PY - 1994

Y1 - 1994

N2 - The suitability of the intraosseous (i.o.) route for drug administration to equine neonates was evaluated in a study comparing the pharmacokinetics of amikacin administered by the i.o. and intravenous (i.v.) routes. Using a cross‐over study design amikacin sulphate (7 mg/kg bwt) was administered i.o. or i.v. to 6 healthy foals at 3 and 5 days of age. Amikacin was instantaneously and completely absorbed after i.o. administration, achieving a mean ± sd peak concentration (34.17 ± 3.54 μg/ml) in the first sample collected 3 min after administration which was not significantly different from the mean ± sd peak concentration (32.92 ± 2.63 μg/ml) achieved after i.v. administration. The plasma amikacin concentration‐time profiles for the i.o. and i.v. routes were not different and both were appropriately described by a 2‐compartment open pharmacokinetic model. No significant differences attributable to route of administration were found in values for the major pharmacokinetic variables. The degree of inter‐individual variation in values for indices of clearance was considerably greater than the degree of variation attributable to age. Despite this, values for body clearance (C***lB) were significantly higher (P<0.05) and values for area under the plasma amikacin concentration‐time curve (AUC) and concentration of amikacin in plasma at 8 h [Cp(8h)] were significantly lower in 5‐ than in 3‐day‐old foals, indicating that amikacin was more rapidly cleared by the older foals. Technical difficulties were not encountered during i.o. needle placement in the medial aspect of the proximal tibia. Mild diffuse soft tissue swelling which developed at the i.o. site resolved completely within 1–2 months. Radiographs demonstrated a bony healing process with minor periosteal and endosteal proliferation. The i.o. route appears to be safe, practical and effective for rapid delivery of amikacin to neonatal foals.

AB - The suitability of the intraosseous (i.o.) route for drug administration to equine neonates was evaluated in a study comparing the pharmacokinetics of amikacin administered by the i.o. and intravenous (i.v.) routes. Using a cross‐over study design amikacin sulphate (7 mg/kg bwt) was administered i.o. or i.v. to 6 healthy foals at 3 and 5 days of age. Amikacin was instantaneously and completely absorbed after i.o. administration, achieving a mean ± sd peak concentration (34.17 ± 3.54 μg/ml) in the first sample collected 3 min after administration which was not significantly different from the mean ± sd peak concentration (32.92 ± 2.63 μg/ml) achieved after i.v. administration. The plasma amikacin concentration‐time profiles for the i.o. and i.v. routes were not different and both were appropriately described by a 2‐compartment open pharmacokinetic model. No significant differences attributable to route of administration were found in values for the major pharmacokinetic variables. The degree of inter‐individual variation in values for indices of clearance was considerably greater than the degree of variation attributable to age. Despite this, values for body clearance (C***lB) were significantly higher (P<0.05) and values for area under the plasma amikacin concentration‐time curve (AUC) and concentration of amikacin in plasma at 8 h [Cp(8h)] were significantly lower in 5‐ than in 3‐day‐old foals, indicating that amikacin was more rapidly cleared by the older foals. Technical difficulties were not encountered during i.o. needle placement in the medial aspect of the proximal tibia. Mild diffuse soft tissue swelling which developed at the i.o. site resolved completely within 1–2 months. Radiographs demonstrated a bony healing process with minor periosteal and endosteal proliferation. The i.o. route appears to be safe, practical and effective for rapid delivery of amikacin to neonatal foals.

KW - amikacin

KW - foal

KW - horse

KW - intraosseous

KW - pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0028512531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028512531&partnerID=8YFLogxK

U2 - 10.1111/j.2042-3306.1994.tb04405.x

DO - 10.1111/j.2042-3306.1994.tb04405.x

M3 - Article

C2 - 7988539

AN - SCOPUS:0028512531

VL - 26

SP - 367

EP - 373

JO - Equine veterinary journal. Supplement

JF - Equine veterinary journal. Supplement

SN - 2042-3306

IS - 5

ER -